These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2292054)

  • 21. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890).
    Dutcher JP; Fine JP; Krigel RL; Murphy BA; Schaefer PL; Ernstoff MS; Loehrer PJ
    Med Oncol; 2003; 20(3):271-81. PubMed ID: 14514977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
    Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
    Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination chemotherapy of advanced renal cell cancer with CCNU and vinblastine.
    Sommer HH; Fosså SD; Lien HH
    Cancer Chemother Pharmacol; 1985; 14(3):277-8. PubMed ID: 3995687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metastatic renal cell carcinoma arising in a congenital solitary kidney. Treatment with interferon-containing combinations. A case report and a review of the literature.
    Merimsky O; Laufer R; Chaitchik S
    J Urol (Paris); 1989; 95(4):243-5. PubMed ID: 2529317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.
    Vogelzang NJ; Lipton A; Figlin RA
    J Clin Oncol; 1993 Sep; 11(9):1809-16. PubMed ID: 8355047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment.
    Huland E; Heinzer H; Huland H
    J Cancer Res Clin Oncol; 1994; 120(4):221-8. PubMed ID: 8288676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.
    George S; Dreicer R; Au JJ; Shen T; Rini BI; Roman S; Cooney MM; Mekhail T; Elson P; Wientjes GM; Ganapathi R; Bukowski RM
    Clin Genitourin Cancer; 2008 Sep; 6(2):79-85. PubMed ID: 18824429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chemotherapy of renal cell carcinoma. II. Adriamycin and carboquone combined chemotherapy].
    Osawa T
    Nihon Hinyokika Gakkai Zasshi; 1986 Nov; 77(11):1805-13. PubMed ID: 3573463
    [No Abstract]   [Full Text] [Related]  

  • 29. Ifosfamide, vindesine and recombinant alpha-interferon combination chemotherapy for metastatic renal cell carcinoma.
    König HJ; Gutmann W; Weissmüller J
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S221-3. PubMed ID: 1795011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer.
    Weinerman B; Eisenhauer E; Stewart D; Mertens W; Tannock I; Venner P; Spaulding R
    Ann Oncol; 1992 Jan; 3(1):83-4. PubMed ID: 1606075
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
    Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of oral ftorafur and uracil in patients with advanced renal cell carcinoma.
    Esteban E; Buesa JM; Cueva J; Fernández Y; Peláez I; Fernández JL; Sanz A; Palacio I; Estrada E; Gracia JM
    Eur J Cancer; 1993; 29A(9):1354. PubMed ID: 8343285
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
    Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
    J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
    Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
    Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.
    Vaishampayan U; Flaherty L; Du W; Hussain M
    Cancer; 2001 Aug; 92(3):519-23. PubMed ID: 11505395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma.
    Tai CJ
    Acta Oncol; 2009; 48(6):931-2. PubMed ID: 19925379
    [No Abstract]   [Full Text] [Related]  

  • 38. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
    Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
    J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma.
    Teló GH; Carvalhal GF; Cauduro CGS; Webber VS; Barrios CH; Fay AP
    Ann Oncol; 2017 Jan; 28(1):191-192. PubMed ID: 28043983
    [No Abstract]   [Full Text] [Related]  

  • 40. Chemotherapy for renal cell carcinoma.
    Amato RJ
    Semin Oncol; 2000 Apr; 27(2):177-86. PubMed ID: 10768596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.